desipramine has been researched along with Burning Mouth Syndrome in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Burning Mouth Syndrome: A group of painful oral symptoms associated with a burning or similar sensation. There is usually a significant organic component with a degree of functional overlay; it is not limited to the psychophysiologic group of disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danhauer, SC | 1 |
| Miller, CS | 1 |
| Rhodus, NL | 1 |
| Carlson, CR | 1 |
1 trial available for desipramine and Burning Mouth Syndrome
| Article | Year |
|---|---|
Impact of criteria-based diagnosis of burning mouth syndrome on treatment outcome.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Anticonvulsants; Burning Mouth Syndrome; Carbam | 2002 |